Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A confirmatory phase III trial of Firdapse in patients with Lambert-Eaton myasthenic syndrome

Next Previous
Trial Profile

A confirmatory phase III trial of Firdapse in patients with Lambert-Eaton myasthenic syndrome

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 31 Aug 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amifampridine (Primary)
  • Indications Lambert-Eaton myasthenic syndrome
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 09 Aug 2016 According to a Catalyst Pharmaceuticals media release, company expects to start this trial in the fourth quarter 2016 and anticipates having two clinical trial sites, one each on the east and west coasts of the U.S.The company will enroll subjects from the company's Expanded Access Programme.
  • 09 Aug 2016 According to a Catalyst Pharmaceuticals media release, company has reached an agreement with the FDA during the quarter on this trial protocol. Company anticipates filling an NDA resubmission based on the top-line data in the second half of 2017.
  • 13 Jun 2016 According to a Catalyst Pharmaceuticals media release, firdapse for the treatment of LEMS has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) and orphan drug designation for LEMS and CMS.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top